  Monitoring Neoadjuvant chemotherapy (NAC) effects is necessary to capture
resistant patients and stop or change treatment. The aim of this study was to
assess the tumor response at an early stage, after the first doses of the NAC,
based on the variability of the backscattered ultrasound energy, and
backscatter statistics. The backscatter statistics has not previously been used
to monitor NAC effects. The B-mode ultrasound images and raw radio frequency
data from breast tumors were obtained using an ultrasound scanner before
chemotherapy and 1 week after each NAC cycle. Twenty-four malignant breast
cancers, qualified for neoadjuvant treatment before surgery, were included in
the study. The shape parameter of the homodyned K distribution and integrated
backscatter, along with the tumor size in the longest dimension, were
determined based on ultrasound data and used as markers for NAC response.
Cancer tumors were assigned to responding and non-responding groups, according
to histopathological evaluation, which was a reference in assessing the utility
of markers. Statistical analysis was performed to rate the ability of markers
to predict NAC response based on data obtained after subsequent therapeutic
doses. Statistically significant differences between groups were obtained after
2, 3, 4, and 5 doses of NAC for quantitative ultrasound markers and after 5
doses for the assessment based on maximum tumor dimension. After the second and
third NAC courses the marker, which was a linear combination of both
quantitative ultrasound parameters, was characterized by an AUC of 0.82 and
0.91, respectively. The introduction of statistical parameters of ultrasonic
backscatter to monitor the effects of chemotherapy can increase the
effectiveness of monitoring and contribute to a better personalization of NAC
therapy.
